Skip to main content
SpringerLink
Log in

Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in differentiated thyroid cancer: a preliminary report

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The purpose of this study was to investigate the clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in patients with differentiated thyroid cancer (DTC).

Methods

We retrospectively analyzed 219 DTC patients who underwent high-dose 131I treatment and subsequent post-therapeutic dual 131I scan. Both early (third day after 131I treatment) and delayed (5–6th day after 131I treatment) 131I scan images were visually assessed and diffuse hepatic uptake was scored using a 4-point grading system depending on intensity.

Results

On early 131I scan, 73 patients (33.4 %) showed diffuse hepatic uptake, while 191 patients (87.2 %) patients showed diffuse hepatic uptake on delayed scan (p < 0.0001). The serum levels of ALT in patients with diffuse hepatic uptake on early scan were higher than those without diffuse hepatic uptake on early scan (p = 0.03 for ALT and p = 0.08 for AST). The serum levels of ALT and AST trended with the grade of hepatic uptake on delayed scan (p = 0.03 for ALT and p = 0.05 for AST). Diffuse hepatic uptake on early or delayed scan showed no significant relationship in the presence of thyroid remnants, metastatic DTC lesions, tumor recurrence during follow-up, and the serum thyroglobulin level (p > 0.05). On logistic regression analysis, both serum ALT (p = 0.01) and AST (p = 0.04) levels were significant predictive factors for diffuse hepatic uptake on early scan, while only serum ALT (p = 0.01) level was significant predictive factor for diffuse hepatic uptake on delayed scan.

Conclusions

The frequency of diffuse hepatic uptake on the delayed scan was significantly higher than the early scan. Diffuse hepatic uptake on early post-therapeutic scan and the intensity of diffuse hepatic uptake on delayed scan showed significant correlation with the serum levels of hepatic enzymes, but no significant association in the presence of thyroid remnants, metastatic DTC lesions, and tumor recurrence during follow-up. The timing and intensity of diffuse hepatic uptake on post-therapeutic scan may be related with factors such as hepatic function other than the thyroid tissue or DTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.

    Article  CAS  PubMed  Google Scholar 

  3. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573–7.

    Article  CAS  PubMed  Google Scholar 

  4. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795–8.

    Article  PubMed  Google Scholar 

  5. McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med. 1995;20:869–75.

    Article  CAS  PubMed  Google Scholar 

  6. Ziessman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualization on iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987;28:1408–11.

    CAS  PubMed  Google Scholar 

  7. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–60.

    Article  CAS  PubMed  Google Scholar 

  8. Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC, Cho BY, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191–5.

    CAS  PubMed  Google Scholar 

  9. Ferris HA, Williams G, Parker JA, Garber JR. Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer. Endocr Pract. 2013;19:263–7.

    Article  PubMed  Google Scholar 

  10. Omur O, Akgun A, Ozcan Z, Sen C, OzkiIic H. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans. Clin Nucl Med. 2009;34:11–4.

    Article  PubMed  Google Scholar 

  11. Tatar FA, Morita E, Ituarte PH, Cavalieri RR, Duh QY, Price DC, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–22.

    Article  CAS  PubMed  Google Scholar 

  12. Lee JW, Lee SM, Koh GP, Lee DH. The comparison of (131)I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report. Ann Nucl Med. 2011;25:439–46.

    Article  PubMed  Google Scholar 

  13. Lee JW, Lee SM, Lee DH, Kim YJ. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013;54:1230–6.

    Article  CAS  PubMed  Google Scholar 

  14. Wakabayashi H, Nakajima K, Fukuoka M, Inaki A, Nakamura A, Kayano D, et al. Double-phase (131)I whole body scan and (131)I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification. Ann Nucl Med. 2011;25:609–15.

    Article  PubMed  Google Scholar 

  15. Salvatori M, Perotti G, Villani MF, Mazza R, Maussier ML, Indovina L, et al. Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nucl Med Commun. 2013;34:900–8.

    PubMed  Google Scholar 

  16. Lee SM, Lee JW, Kim SY, Han SW, Bae WK. Prediction of risk for symptomatic sialadenitis by post-therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer. Ann Nucl Med. 2013;27:700–9.

    Article  PubMed  Google Scholar 

  17. Maayan ML, Eisenberg J, Lopez EM, Rothschild MA. Hepatic visualization after 131I in patients with thyroid carcinoma. N Engl J Med. 1976;295:1258–9.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Soonchunhyang University Research Fund.

Conflict of interest

No potential conflicts of interest were disclosed.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Catholic Kwandong University International St. Mary’s Hospital, Incheon, Korea

    Jeong Won Lee

  2. Department of Nuclear Medicine, Soonchunhyang University Hospital, 23-20, Byeongmyeong-dong, Dongnam-gu, Cheonan, Chungcheongnam-do, 330-721, Korea

    Sang Mi Lee & Jiyoun Choi

Authors
  1. Jeong Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Mi Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiyoun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang Mi Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, J.W., Lee, S.M. & Choi, J. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in differentiated thyroid cancer: a preliminary report. Ann Nucl Med 29, 190–197 (2015). https://doi.org/10.1007/s12149-014-0929-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-014-0929-3

Keywords

Search

Navigation